Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The University of Dundee's Drug Discovery Unit (DDU) collaboration with Medicines for Malaria Venture (MMV) has identified an oral compound to treat malaria in mouse model at very low doses.
Subscribe to our email newsletter
The project commenced after the biology team at the DDU screened one of their collections of compounds against the malaria parasite, healthcanal.com reported.
Over a span of 18 months, two such compounds were refined through cycles of compound design, chemical synthesis and biological testing.
MMV chief scientific officer Tim Wells said Malaria control has been a cause for concern and the current effective treatment, artemisinin is developing resistance.
"In preparation for this eventuality MMV and partners are researching over 50 projects in the largest-ever pipeline of antimalarial medicines," Wells added.
The University’s Drug Discovery Unit has the remit of developing translational research at Dundee and outside.
MMV, a Swiss-based foundation, is recognized as a product development partnership (PDP) in the field of antimalarial drug research and development.